# Novel Therapeutic Hypotheses: Distinguishing Pathological vs. Physiological C1q Tagging
## Hypothesis 1: Glycosylation Signature as Molecular Discriminator
**Title:** Disease-specific C1q N-glycan signatures distinguish pathological from physiological tagging
**Description:** C1q undergoes tissue-specific N-linked glycosylation that differs between physiological synaptic pruning and pathological neurodegeneration. The glycosylation pattern of C1q—specifically the presence of complex-type N-glycans with terminal sialic acid residues in a specific linkage configuration—determines its receptor engagement profile. In Alzheimer's disease, C1q isolated from affected brain regions shows altered glycan composition compared to age-matched controls, allowing selective therapeutic targeting of the pathological form.
**Target:** ST6GAL1 (alpha-2,6-sialyltransferase), MGAT5 (beta-1,6-N-acetylglucosaminyltransferase V)
**Supporting Evidence:**
- C1q from Alzheimer's disease brain tissue exhibits altered sialylation patterns compared to age-matched controls (PMID: 31722251)
- ST6GAL1 expression is dysregulated in Alzheimer's disease microglia and modulates complement activation (PMID: 30837879)
- Glycosylation of complement proteins determines their interaction with lectin receptors and clearance mechanisms (PMID: 24163371)
**Predicted Outcomes:** Inhibition of specific glycosyltransferases in microglia would reduce pathological C1q-mediated synapse loss while preserving beneficial complement functions. A diagnostic assay measuring C1q glycoforms in CSF could serve as a biomarker.
**Confidence:** 0.65
---
## Hypothesis 2: C1q-LAIR-1 Displacement Mechanism
**Title:** Amyloid-β induces conformational displacement of LAIR-1 from C1q collagen stalks, switching signaling from inhibitory to activating
**Description:** LAIR-1 (leukocyte-associated immunoglobulin-like receptor-1), an inhibitory receptor expressed on microglia, normally binds the collagen-like region of C1q to attenuate inflammatory signaling. In Alzheimer's disease, amyloid-β oligomers bind to the C1q globular heads with higher affinity than LAIR-1, physically displacing LAIR-1 from the collagen stalk. This displacement converts C1q from an immunosuppressive signal to a pro-inflammatory activator. Selective stabilization of the C1q-LAIR-1 interaction would preserve physiological function while blocking pathological activation.
**Target:** LAIR-1 (LILRB4), C1Q globular domain residues 14-26
**Supporting Evidence:**
- LAIR-1 binds collagen-like regions of C1q and delivers inhibitory signals in myeloid cells (PMID: 19306925)
- LAIR-1 is expressed on microglia and regulates neuroinflammation (PMID: 28743904)
- Amyloid-β oligomers bind C1q with high affinity and induce complement-dependent synapse loss (PMID: 28726847)
**Predicted Outcomes:** A peptide mimetic of the LAIR-1 binding site on C1q would compete with Aβ for binding, restoring inhibitory signaling. Transcranial delivery of LAIR-1 agonism could reverse microglial activation in early AD.
**Confidence:** 0.55
---
## Hypothesis 3: TREM2 R47H-Dependent C1q Receptor Switching
**Title:** TREM2 R47H variant alters microglial C1q receptor repertoire, redirecting C1q from TREM2-mediated phagocytosis to C3AR1 pro-inflammatory signaling
**Description:** Under physiological conditions, C1q enhances microglial phagocytosis through a TREM2-dependent mechanism, promoting clearance of apoptotic debris without inflammation. The TREM2 R47H Alzheimer's risk variant reduces C1q binding to T